Perform Another (Advanced) Search

1.  CenterWatch: Clinical Trials in Category (630) Pelvic Adhesions
...CenterWatch: Clinical Trials in Category (630) Pelvic Adhesions Pelvic Adhesions State • New York New York Great Neck : Biomedical Research Alliance of New York Pelvic Organ ...
View Page

2.  Study Posting (77) Trial #155988, Pelvic Adhesions, Great Neck, NY
...Study Posting (77) Trial #155988, Pelvic Adhesions, Great Neck, NY Trial Information Pelvic Organ Prolapse- Females Females with Pelvic Organ Prolapse are ...
...Alliance of New York support@centerwatch.com kiger@nshs.edu Pelvic Organ Prolapse- Females Pelvic Adhesions Great Neck, NY 155988 Clinical Trial Participation If you would like to learn more about ...
View Page

3.  News: ARISE Trials Shows Promising Results for Diabetes (Clinical Trials Today)
...results from a phase III trial of succinobucol (AGI-1067), an antioxidant oral vascular cell adhesion molecule-1 (VCAM-1) gene expression inhibitor, for the treatment of diabetes and coronary heart ...
View Page

4.  Newly Approved Drug Therapies (973) Tysabri (natalizumab), Biogen IDEC,
...alpha-4-beta-7. The receptors for the a4 family of integrins include vascular cell adhesion molecule-1 (VCAM-1), which is expressed on activated vascular endothelium, and mucosal addressin cell adhesion molecule-1 (MAdCAM-1) present on vascular endothelial cells of the gastrointestinal tract. It is ...
View Page

5.  Newly Approved Drug Therapies (155) Seprafilm, Genzyme,
...open surgery as an adjunct intended to reduce the incidence, extent, and severity of postoperative adhesions (scar tissues) between the abdominal wall and the underlying viscera such as omentum, small bowel ...
...pain) has not yet been studied, but two clinical trials have shown that Seprafilm reduced adhesion formation where the membrane was placed. Jobson Medical Information • Privacy | • Glossary Copyright © 1995-2010 Jobson ...
View Page

6.  Newly Approved Drug Therapies (1078) Wilate (von Willebrand Factor/Coagulation Factor VIII Complex (Human), Octapharma,
...bleeding. The administration of VWF allows for the following: 1) The VWF re-establishes platelet adhesion, providing primary hemostasis, as shown by the shortening of the bleeding time, and 2) The ...
...the hemostatic abnormalities in VWD patients at two levels: 1) The VWF re-establishes platelet adhesion to the vascular sub-endothelium at the site of vascular damage, providing primary hemostasis, as ...
View Page

7.  CenterWatch: Clincial Trial Listings in Obstetrics/Gynecology
...Menopause   (21, 5 New! ) Menstrual Disorders   (6) Menstruation   (6) Ovarian Cancer   (261, 2 New! ) Pelvic Adhesions   (1) Polycystic Ovarian Syndrome   (160, 1 New! ) Post Menopause   (17, 1 New! ) Post-Menopausal Osteopenia ...
View Page

8.  CenterWatch Trial Listings By Disease Category
...1, 1 New! ) Parkinson's Disease   (16, 1 New! ) Pediatric Health   (8, 1 New! ) Pelvic Adhesions   (1) Pemphigus Vulgaris (PV)   (13) Periodontitis   (1) Peripheral Arterial Disease (PAD)   (14) Peripheral Arterial Occlusive ...
View Page

9.  Study Posting (5460) Trial #161589, Uterine Fibroids, Charlottesville, VA
...with increasing morbidity risks including, but not limited to, infection, blood loss and postoperative uterine adhesions. ExAblate is approved by FDA for the treatment of uterine fibroids; however, its use in ...
View Page

10.  Study Posting (5460) Trial #158791, Uterine Fibroids, Plano, TX
...with increasing morbidity risks including, but not limited to, infection, blood loss and postoperative uterine adhesions. ExAblate is approved by FDA for the treatment of uterine fibroids; however, its use in ...
View Page

11.  Study Posting (5460) Trial #158797, Uterine Fibroids, Durham, NC
...with increasing morbidity risks including, but not limited to, infection, blood loss and postoperative uterine adhesions. ExAblate is approved by FDA for the treatment of uterine fibroids; however, its use in ...
View Page

12.  Study Posting (5460) Trial #158795, Uterine Fibroids, Rochester, MN
...with increasing morbidity risks including, but not limited to, infection, blood loss and postoperative uterine adhesions. ExAblate is approved by FDA for the treatment of uterine fibroids; however, its use in ...
View Page

13.  Study Posting (5460) Trial #158799, Uterine Fibroids, Smyrna, GA
...with increasing morbidity risks including, but not limited to, infection, blood loss and postoperative uterine adhesions. ExAblate is approved by FDA for the treatment of uterine fibroids; however, its use in ...
View Page

14.  Study Posting (5460) Trial #158801, Uterine Fibroids, Los Angeles, CA
...with increasing morbidity risks including, but not limited to, infection, blood loss and postoperative uterine adhesions. ExAblate is approved by FDA for the treatment of uterine fibroids; however, its use in ...
View Page

15.  Study Posting (5460) Trial #161590, Infertility, Charlottesville, VA
...with increasing morbidity risks including, but not limited to, infection, blood loss and postoperative uterine adhesions. ExAblate is approved by FDA for the treatment of uterine fibroids; however, its use in ...
View Page

16.  Study Posting (5460) Trial #158792, Infertility, Plano, TX
...with increasing morbidity risks including, but not limited to, infection, blood loss and postoperative uterine adhesions. ExAblate is approved by FDA for the treatment of uterine fibroids; however, its use in ...
View Page

17.  Study Posting (5460) Trial #158798, Infertility, Durham, NC
...with increasing morbidity risks including, but not limited to, infection, blood loss and postoperative uterine adhesions. ExAblate is approved by FDA for the treatment of uterine fibroids; however, its use in ...
View Page

18.  Study Posting (5460) Trial #158796, Infertility, Rochester, MN
...with increasing morbidity risks including, but not limited to, infection, blood loss and postoperative uterine adhesions. ExAblate is approved by FDA for the treatment of uterine fibroids; however, its use in ...
View Page

19.  Study Posting (5460) Trial #158800, Infertility, Smyrna, GA
...with increasing morbidity risks including, but not limited to, infection, blood loss and postoperative uterine adhesions. ExAblate is approved by FDA for the treatment of uterine fibroids; however, its use in ...
View Page

20.  Study Posting (5460) Trial #158802, Infertility, Los Angeles, CA
...with increasing morbidity risks including, but not limited to, infection, blood loss and postoperative uterine adhesions. ExAblate is approved by FDA for the treatment of uterine fibroids; however, its use in ...
View Page